Akrevia Therapeutics is a privately-held biopharmaceutical company focused on developing highly-potent, targeted immuno-oncology therapeutics. The company's proprietary Aklusion platform technology allows biologics to be specifically activated in the tumor microenvironment, and with precisely tailored properties, expanding the universe of immune-activating proteins that can be safely delivered. Akrevia is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for patients living with cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/27/18 | $30,000,000 | Series A |
Atlas Venture F-Prime Capital Partners | undisclosed |
